Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naive or Treatment-Experienced
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyun Woong | - |
dc.contributor.author | Yoo, Ki Young | - |
dc.contributor.author | Won, Joung Won | - |
dc.contributor.author | Kim, Hyung Joon | - |
dc.date.available | 2019-03-08T07:57:55Z | - |
dc.date.issued | 2017-09 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/3999 | - |
dc.description.abstract | Background/Aims: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. Methods: Patients (n=30) were enrolled between September 2015 and April 2016. Twenty-six patients were genotype 1 (1b, n=21; 1a, n=5) and four patients were genotype 2a/2b. Among 21 patients with genotype lb, Y93H resistance-associated variants (RAVs) were detected in three patients (14.3%). We evaluated sustained virologic response (SVRs) at 12 weeks, as well as relapse and safety. Results: Five patients with genotype la and three patients with genotype lb (RAV positive) received ledipasvir/sofosbuvir for 12 weeks. SVR12 rate was 100% (8/8). Eleven patients with genotype lb were treatment-naive and received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 91% (10/11). One patient experienced viral breakthrough without RAV at 12 weeks. Seven treatment experienced patients with genotype lb received daclatasvir plus asunaprevir for 24 weeks. SVR12 rate was 85.7% (6/7). One patient experienced viral breakthrough with RAV (L31M, Y93H) at 12 weeks. Four patients with genotype 2a/2b received sofosbuvir plus ribavirin for 12 weeks. SVR12 rate was 100% (4/4). No serious adverse event-related discontinuations were noted. Conclusions: New direct acting antiviral treatment achieved high SVRs rates at 12 weeks in CHC patients with hemophilia without serious adverse events. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | EDITORIAL OFFICE GUT & LIVER | - |
dc.title | Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naive or Treatment-Experienced | - |
dc.type | Article | - |
dc.identifier.doi | 10.5009/gnl17209 | - |
dc.identifier.bibliographicCitation | GUT AND LIVER, v.11, no.5, pp 721 - 727 | - |
dc.identifier.kciid | ART002262855 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000411046200019 | - |
dc.identifier.scopusid | 2-s2.0-85032002466 | - |
dc.citation.endPage | 727 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 721 | - |
dc.citation.title | GUT AND LIVER | - |
dc.citation.volume | 11 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | chronic | - |
dc.subject.keywordAuthor | Sofosbuvir | - |
dc.subject.keywordAuthor | Ledipasvir | - |
dc.subject.keywordAuthor | Daclatasvir | - |
dc.subject.keywordAuthor | Asunaprevir | - |
dc.subject.keywordPlus | DACLATASVIR PLUS ASUNAPREVIR | - |
dc.subject.keywordPlus | GENOTYPE 1 INFECTION | - |
dc.subject.keywordPlus | SUSTAINED VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | LEDIPASVIR-SOFOSBUVIR | - |
dc.subject.keywordPlus | BLEEDING DISORDERS | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | HCV | - |
dc.subject.keywordPlus | RIBAVIRIN | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.